Modelos europeos de telemedicina, como el servicio finlandés Medilux, permiten realizar consultas médicas online mediante un cuestionario clínico, sin acudir a una consulta presencial.

The new HTA guides 2017 could be up to their predecessors

From the first reports, back in 1920, we have studied, recognized and documented the excess of events associated with arterial hypertension. This linear relationship between the level of blood pressure and the risk of stroke, is evident in all adults beyond age, sex or race, transforming high blood pressure into the highest target of global public health.

Las nuevas guías Europeas de Hipertensión contrastan con las Americanas

The greatest impact of reducing hypertension was observed in adults between 60 and 74 years, where a decrease in systolic pressure from 148 to 129 mm Hg led to a 50% reduction in stroke risk, and a decrease from 188 to 156 mm Hg to a reduction of 90% of the risk!


Read also: New High Blood Pressure Guidelines.


These lower levels of blood pressure observed were, obviously, thanks to the pharmacological treatment of this age group. However, lower levels were also observed in the group between 20 and 29 years, which suggests that prevention and non-pharmacological treatment are also very effective.

From the end of the 90s until 2017, the evidence from randomized clinical studies and epidemiological studies was incorporated into the guidelines to detect, treat, control and prevent hypertension in the most effective way possible.

With each new guide that redefined objectives and improved treatment protocols, a decrease in the population’s blood pressure and a reduction in stroke risk was observed. These improvements cannot be attributed to the guidelines themselves, but rather to the implementation by doctors of their recommendations in daily clinical practice.


Read also: Patients with Resistant Hypertension: Nearly 50% doesn’t take medication.


The reduction in the risk of stroke due to the decrease in blood pressure has been proposed as the greatest achievement of public health in the last 50 years. This achievement is not more than the result of the application in daily clinical practice of recommendations based on evidence and adherence to treatment by patients.

We hope that the ambitious recommendations of the new hypertension guidelines of 2017 can continue with the trend of their predecessors, since there is still a huge potential in improving the cerebrovascular health of the population.

Original title: Implications of New High Blood Pressure Guidelines for Stroke Primary and Secondary Prevention.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

EuroPCR 2026 | P2Y12 Inhibitor Monotherapy After Complex PCI in ACS: Results From the NEO-MINDSET COMPLEX Subanalysis

This is a summary of the NEO-MINDSET COMPLEX subanalysis, presented by Dr. Guy Prado at EuroPCR 2026, which evaluated P2Y12 inhibitor monotherapy versus dual...

EuroPCR 2026 | Evolocumab Reduces Cardiovascular Events in Patients With Prior PCI Without Previous Myocardial Infarction: VESALIUS-CV Results

This presentation, delivered by Dr. Brian A. Bergmark and colleagues at EuroPCR 2026, detailed the results of the VESALIUS-CV trial, focusing specifically on the...

EuroPCR 2026 | Is It Safe to Stop Aspirin After One Month in MI Patients Undergoing PCI? TARGET-FIRST Analysis

This is a summary of the post-hoc analysis of the TARGET-FIRST study, presented by Dr. Giuseppe Tarantini at EuroPCR 2026, evaluating early aspirin discontinuation...

EuroPCR 2026 | Could clopidogrel replace aspirin as monotherapy after PCI?

This presentation, delivered during EuroPCR 2026, analyzed the clinical outcomes of clopidogrel monotherapy versus aspirin in patients who remained event-free for 12 months after...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img
Jornadas Guatemala 2026

Recent Articles

EuroPCR 2026 | TAVI or Surgery in Younger Patients? Quality of Life and 3-Year Outcomes from NOTION-2

The expansion of TAVI into younger and lower surgical-risk populations has sparked a new debate: beyond mortality and stroke, which strategy provides better functional...

EuroPCR 2026 | MELA Registry: Myval Showed Lower Aortic Regurgitation Rates in Patients With Large Aortic Annuli

This presentation, delivered by Dr. Salvatore Giordano at EuroPCR 2026, detailed the results of the MELA Registry, a multicenter study comparing the performance of...

EuroPCR 2026 | LANDMARK Trial: Two-Year Results Showed Comparable Efficacy Between Myval and Contemporary TAVI Valves

The LANDMARK trial presentation, delivered by Prof. Patrick W. Serruys at EuroPCR 2026, detailed the two-year clinical outcomes of contemporary transcatheter aortic valve implantation...